Trial Profile
A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 09 Jun 2019 Trial has been discontinued in Spain according to European Clinical Trials Database record.
- 16 Feb 2010 104-week results published in the International Journal of Obesity.
- 05 May 2009 Trial phase changed from II to III as reported by ClinicalTrials.gov.